We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Viridian Therapeutics Inc. is a biotechnology company advancing new treatments for patients suffering from serious diseases. The company's program includes VRDN-001, which is in clinical stage. Viridian Therapeutics Inc., formerly known as miRagen Therapeutics Inc., is based in BOULDER, Colo.
- Recent VRDN Stock Price: $36.02
- Yearly Gain for VRDN stock: 82.89%
- Market Cap for VRDN stock: $1.42B
- P/E Ratio for VRDN stock: -8.402
Will VRDN's stock price go up? Is there an accurate VRDN stock forecast available?
TipRanks.com reports that Viridian Therapeutics currently has 11 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $45.73. The target pricing ranges from a high VRDN forecast of $62.00 down to a low forecast of $35.00. Viridian Therapeutics (VRDN)’s last closing stock price was $36.02 which would put the average price target at 26.96% upside.
In addition, TradingView issued a Buy rating for VRDN stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on VRDN stock.
Other analysts covering VRDN include:
- Michael Higgins of Ladenburg Thalmann & Co. issued a Buy rating with the price target of $ 40 on 3 days ago
- Kalpit Patel of B.Riley Financial issued a Buy rating with the price target of $ 46 on 3 days ago
- Thomas Smith of SVB Securities issued a Buy rating with the price target of $ 45 on 4 days ago
- Douglas Tsao of H.C. Wainwright issued a Buy rating with the price target of $ 35 on 4 days ago
If you are wondering if VRDN is a good stock to buy, here are 3rd party ratings for VRDN stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 24% (59 out of 250)
What is the sentiment on the street regarding Viridian Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for VRDN stock: Very Bullish
- Blogger Consensus for VRDN stock: Bullish
- Media Buzz for VRDN stock: Very High
- Insider Signal for VRDN stock: n/a
- Investor Sentiment for VRDN stock: Very Positive
- Hedge Fund signal for VRDN stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on VRDN stock including scouring the social networks like VRDN StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for VRDN stock chart >>
Summary: AstraZeneca PLC was incorporated in England and Wales on 17 June 1992. From February 1993 until April 1999, the Company was called Zeneca Group PLC. On 6 April 1999, the Company changed its name to AstraZeneca PLC. It is a biopharmaceutical company. The Company focuses on three important areas of healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). The Company is also engaged in the Infection, Neuroscience and Gastrointestinal (ING) disease areas. It operates in more than 100 countries.
- Recent AZNCF Stock Price: $138.66
- Yearly Gain for AZNCF stock: 40.45%
- Market Cap for AZNCF stock: $219.23B
- P/E Ratio for AZNCF stock: 117.315
Will AZNCF's stock price go up? Is there an accurate AZNCF stock forecast available?
TipRanks.com reports that AstraZeneca currently has 13 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $164.71. The target pricing ranges from a high AZNCF forecast of $237.31 down to a low forecast of $94.25. AstraZeneca (AZNCF)’s last closing stock price was $138.66 which would put the average price target at 18.78% upside.
In addition, TradingView issued a Strong Buy rating for AZNCF stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on AZNCF stock.
Other analysts covering AZNCF include:
- Michael Leuchten of UBS issued a Hold rating with the price target of $ 123.53 on 4 days ago
- James Gordon of J.P. Morgan issued a Buy rating with the price target of $ 165.12 on 4 days ago
- Emily Field of Barclays issued a Buy rating with the price target of $ 152.89 on 4 days ago
- Dominic Lunn of Credit Suisse issued a Hold rating with the price target of $ 144.33 on 1 week ago
If you are wondering if AZNCF is a good stock to buy, here are 3rd party ratings for AZNCF stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Strong Buy
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: n/a, n/a
What is the sentiment on the street regarding AstraZeneca? (Current ratings compiled by TipRanks.com)
- News Sentiment for AZNCF stock: Very Bullish
- Blogger Consensus for AZNCF stock: n/a
- Media Buzz for AZNCF stock: Medium
- Insider Signal for AZNCF stock: Negative
- Investor Sentiment for AZNCF stock: n/a
- Hedge Fund signal for AZNCF stock: No Signal
The stock market is extremely volatile, and you need to do your own research on AZNCF stock including scouring the social networks like AZNCF StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for AZNCF stock chart >>
Summary: Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States.
- Recent ARVN Stock Price: $30.86
- Yearly Gain for ARVN stock: -54.62%
- Market Cap for ARVN stock: $1.61B
- P/E Ratio for ARVN stock: -6.373
Will ARVN's stock price go up? Is there an accurate ARVN stock forecast available?
TipRanks.com reports that Arvinas Holding Company currently has 16 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $75.00. The target pricing ranges from a high ARVN forecast of $100.00 down to a low forecast of $27.00. Arvinas Holding Company (ARVN)’s last closing stock price was $30.86 which would put the average price target at 143.03% upside.
In addition, TradingView issued a Neutral rating for ARVN stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ARVN stock.
Other analysts covering ARVN include:
- Zegbeh Jallah of Capital One Financial issued a Buy rating with the price target of $ 88 on 1 day ago
- Tazeen Ahmad of Bank of America Securities issued a Buy rating with the price target of $ 69 on 3 days ago
- Etzer Darout of BMO Capital issued a Buy rating with the price target of $ 86 on 3 days ago
- Mark Breidenbach of Oppenheimer issued a Buy rating with the price target of $ 95 on 3 days ago
If you are wondering if ARVN is a good stock to buy, here are 3rd party ratings for ARVN stock:
- TipRanks.com: Strong Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 24% (59 out of 250)
What is the sentiment on the street regarding Arvinas Holding Company? (Current ratings compiled by TipRanks.com)
- News Sentiment for ARVN stock: Neutral
- Blogger Consensus for ARVN stock: Bearish
- Media Buzz for ARVN stock: Very Low
- Insider Signal for ARVN stock: n/a
- Investor Sentiment for ARVN stock: Very Negative
- Hedge Fund signal for ARVN stock: Neutral
The stock market is extremely volatile, and you need to do your own research on ARVN stock including scouring the social networks like ARVN StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ARVN stock chart >>
Summary: Sanofi was incorporated under the laws of France in 1994 as a société anonyme, a form of limited liability company. It is a healthcare company, engaged in the research, development, manufacture and marketing of healthcare products. Its principal activities include Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. It also operates through the following platforms: Emerging Markets, Diabetes Solutions, Vaccines, Consumer Health Care (CHC), Animal Health, Genzyme, and Other Innovative Products. The Pharmaceuticals segment covers research, development, production and marketing of medicines, including activities acquired with Genzyme. Sanofi's pharmaceuticals portfolio consists of flagship products, plus prescription medicines, generic medicines, and consumer health products. This segment also includes all associates and joint ventures whose activities are related to pharmaceuticals, in particular the entities majority owned by BMS. The Vaccines segment is wholly dedicated to vaccines, including research, development, production and marketing. This segment includes Sanofi Pasteur MSD joint venture with Merck & Co., Inc. in Europe. The Animal Health segment comprises the research, development, production and marketing activities of Merial, which offers medicines and vaccines for a wide variety of animal species. Its competitors include Novo Nordisk, Merck, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Shire, Pfizer, Biogen Idec, Teva and Merck Serono, Bayer, Roche, Johnson & Johnson, AstraZeneca, Boehringer-Ingelheim, Fresenius Medical Care, among others. The Company's products and manufacturing facilities are subject to significant government regulations and approvals.
- Recent SNYNF Stock Price: $99.35
- Yearly Gain for SNYNF stock: -3.39%
- Market Cap for SNYNF stock: $122.12B
- P/E Ratio for SNYNF stock: 16.296
Will SNYNF's stock price go up? Is there an accurate SNYNF stock forecast available?
TipRanks.com reports that Sanofi currently has 15 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $114.20. The target pricing ranges from a high SNYNF forecast of $144.27 down to a low forecast of $91.52. Sanofi (SNYNF)’s last closing stock price was $99.35 which would put the average price target at 14.95% upside.
In addition, Barchart.com has a buy rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on SNYNF stock.
Other analysts covering SNYNF include:
- Michael Leuchten of UBS issued a Hold rating with the price target of $ 100.13 on 4 days ago
- Mark Purcell of Morgan Stanley issued a Hold rating with the price target of $ 109.82 on 1 week ago
- Dominic Lunn of Credit Suisse issued a Buy rating with the price target of $ 122.74 on 1 week ago
- Peter Welford of Jefferies issued a Buy rating with the price target of $ 129.2 on 1 week ago
If you are wondering if SNYNF is a good stock to buy, here are 3rd party ratings for SNYNF stock:
- TipRanks.com: Moderate Buy
- TradingView.com: n/a (possibly response change)
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: buy
- Zacks.com: n/a, n/a
What is the sentiment on the street regarding Sanofi? (Current ratings compiled by TipRanks.com)
- News Sentiment for SNYNF stock: Very Bullish
- Blogger Consensus for SNYNF stock: n/a
- Media Buzz for SNYNF stock: Low
- Insider Signal for SNYNF stock: n/a
- Investor Sentiment for SNYNF stock: Negative
- Hedge Fund signal for SNYNF stock: No Signal
The stock market is extremely volatile, and you need to do your own research on SNYNF stock including scouring the social networks like SNYNF StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for SNYNF stock chart >>
Summary: Oak Street Health Inc. is a primary care centers for adults on Medicare. It operates principally in Illinois, Michigan, Indiana, Pennsylvania, Ohio, Rhode Island, North Carolina, Tennessee and Texas. Oak Street Health Inc. is based in Chicago, United States.
- Recent OSH Stock Price: $29.94
- Yearly Gain for OSH stock: 25.21%
- Market Cap for OSH stock: $7.17B
- P/E Ratio for OSH stock: -13.011
Will OSH's stock price go up? Is there an accurate OSH stock forecast available?
TipRanks.com reports that Oak Street Health currently has 6 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $29.00. The target pricing ranges from a high OSH forecast of $35.00 down to a low forecast of $21.00. Oak Street Health (OSH)’s last closing stock price was $29.94 which would put the average price target at -3.14% upside.
In addition, TradingView issued a Buy rating for OSH stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on OSH stock.
Other analysts covering OSH include:
- Whit Mayo of SVB Securities issued a Hold rating with the price target of $ 33 on 3 days ago
- Andrew Mok CFA of UBS issued a Hold rating with the price target of $ 21 on 1 week ago
If you are wondering if OSH is a good stock to buy, here are 3rd party ratings for OSH stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Buy, Bottom 17% (207 out of 250)
What is the sentiment on the street regarding Oak Street Health? (Current ratings compiled by TipRanks.com)
- News Sentiment for OSH stock: Very Bullish
- Blogger Consensus for OSH stock: n/a
- Media Buzz for OSH stock: Very High
- Insider Signal for OSH stock: n/a
- Investor Sentiment for OSH stock: Very Positive
- Hedge Fund signal for OSH stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on OSH stock including scouring the social networks like OSH StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for OSH stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================